Showing results (61-70 of 79) with videos related to
Sort By:
Pageof 8
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2014
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantationCésar O Freytes, Juan J Toro, Rosa F Yeh, et al.The Lancet. Oncology|July 15, 2022
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 studyAlison Sehgal, Daanish Hoda, Peter A Riedell, et al.Transplantation and Cellular Therapy|October 3, 2025
Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic TransplantationShannon R McCurdy, Scott R Solomon, Brian C Shaffer, et al.Transplantation and Cellular Therapy|January 4, 2025
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisCindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.Blood Advances|May 22, 2024
Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysisNosha Farhadfar, Nahid Rashid, Karen Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.Blood Advances|April 30, 2025
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT studyAlison Sehgal, Daanish Hoda, Peter A Riedell, et al.Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.Blood Neoplasia|January 15, 2026
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trialGiovanni Martinelli, Scott R Solomon, Sudipto Mukherjee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.Pageof 8